Introduction
phin (HCG; Mochida Pharmacological Corp., Tokyo, Japan) in 0.2 ml Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic of saline at 8:00-8:30 a.m. on the fifth day (26th day of life). complication of the ovulation induction for infertility, especiGroup II ally in patients for whom methods using exogenous gonadotroSix rats were given 10 IU eCG at the time indicated above on the phins are attempted. Although the severe form of OHSS is 24th day of life, and were given 10 IU HCG 48 h later (26th day of life). rare, it is potentially life-threatening (Golan et al., 1989) . It is
Control group
widely accepted that the major clinical components of this As a control, six rats were given the same dosage of 0.9% saline for syndrome are marked enlargement of the ovaries containing 5 consecutive days, from the 22nd to 26th day of life.
The ovarian weights of all rats were determined, expressed as the luteal cysts and haemorrhagic cysts along with the shifting of Values are expressed as the means Ϯ SEM. Those which are significantly different are connected by rules: a P Ͻ 0.05; b P Ͻ 0.03; c P Ͻ 0.01; d P Ͻ 0.0001 respectively. Group I (n ϭ 6): received 10 IU of eCG for 4 consecutive days starting on the 22nd day of life followed by 30 IU of HCG on the fifth day (26th day of life). Group II (n ϭ 6): received a single injection of 10 IU of eCG on the 24th day of life followed by 10 IU of HCG 48 h later (on the 26th day of life). Control group (n ϭ 6): received normal saline instead of eCG/HCG.
total weight of bilateral ovaries. The peritoneal and ovarian capillary concentrations of oestradiol and progesterone were measured using commercially available radioimmunoassay kits (DPC oestradiol kit permeability and the serum concentrations of oestradiol and progesterone were determined as described below at 48 h after the last injection.
and DPC progesterone kit; COAT-A COUNT, Diagnostic Products Co., Los Angeles, CA, USA). The samples for progesterone assay Stimulation protocol and administration of RU486
were diluted before measurement because of their high concentration. A total of 96 rats was given a subcutaneous injection of 10 IU eCG in 0.2 ml of 0.9% saline at 8:00-8:30 a.m. for 4 consecutive days, Measurement of plasma adrenocorticotrophic hormone (ACTH) and were given 30 IU HCG in 0.2 ml of saline at 8:00-8:30 a.m. on concentrations the fifth day. On the sixth day, the animals were divided into eight Another group of 42 immature female rats was prepared for the groups of 12 rats each as follows.
measurement of plasma ACTH concentration, which was employed Groups 1-7: 12 rats in each group were injected subcutaneously to detect the anti-glucocorticoid effect of RU486 in the hyperstimulwith 0, 1, 2.5, 5, 10, 15 or 20 mg/kg of RU486 (RU38486, Rousselated rats. Uclaf, Romainville, France) dissolved in 0.2 ml of 70% ethanol at Thirty-six rats were given a subcutaneous injection of 10 IU of 24 h after the HCG injection.
eCG at 8:00-8:30 a.m. for 4 consecutive days, and were given 30 IU Group 8: 12 rats were injected with 5 mg/kg of RU486 and 10 of HCG at 24 h after the last injection (on the fifth day). On the sixth mg/kg progesterone (6α-methyl-17α-hydroxy-progesterone acetate, day, the animals were divided into six groups as follows: six rats in Sigma Chemicals, St Louis, MO, USA) 24 h after the HCG injection.
each group were injected subcutaneously with 0, 1, 5, 10, 15 or 20 mg/kg of RU486 dissolved in 70% ethanol at 24 h after the Measurement of peritoneal and ovarian capillary permeability and HCG injection.
steroid hormone assays
As a control, six rats received normal saline and ethanol instead On the 28th day of life, 48 h after the HCG injection, under inhalation of eCG/HCG and RU486, respectively, at the times indicated above. anaesthesia by diethyl-ether (Wako Pure Chemicals, Osaka, Japan), At 8:00-8:30 a.m. on the seventh day, animals were decapitated rats were injected via the femoral vein with 0.2 ml of Evans blue and trunk blood was obtained (Carey et al., 1995) . Blood samples dye (EB; Sigma) solution prepared in distilled water at a concentration were collected in iced EDTA-coated tubes, and centrifuged at 3000 of 5 mM. Thirty min after the EB injection, the peritoneal cavity was r.p.m. for 10 min at 4°C. The plasma preparations were stored at irrigated with 5 ml of 0.9% saline (21°C, pH 6.0) according to a -40°C until assayed. modification of the method of Whittle (1964) and Khanna et al. (1990) .
The plasma ACTH concentrations were determined using a comThe peritoneal irrigated fluid was collected into tubes containing 0.05 mercially available enzyme immunoassay kit (PENINSULA EIAH ml of 0.1 N sodium hydroxide solution in order to clear any turbidity 8502, Peninsula Laboratories, CA, USA). This assay kit is designed due to protein, and the tubes were centrifuged at 900 g for 10 min
for the ACTH analysis of rats, and its intra-and inter-assay are Ͻ5% at room temperature. Immediately after the peritoneal irrigation, blood and Ͻ14%, respectively. samples were obtained by puncture of the inferior vena cava for steroid hormone assays as described below. The heart was then Statistical analyses clamped, the right atrium was incised to allow the outflow of perfusate, All data are presented as the mean Ϯ SEM. Statistical analysis was and the systemic circulation was perfused of blood with 50 ml saline performed by one-factor analysis of variance (ANOVA) followed (21°C, pH 6.0) according to a modification of the method of Boschetto by Fisher's protected least significant difference test for multiple et al. (1991) , and then the ovaries were removed. After being weighed, comparisons. The level of significance was set at P ϭ 0.05. the ovaries were incubated in 4 ml of 65°C formamide (N, N-dimethyl formamide, Nacalai Tesque, Kyoto, Japan) for 24 h.
The EB concentrations of the peritoneal irrigated fluid and the
Results
formamide extract of the ovaries were determined by measuring the light absorption at 600 nm with a spectrophotometer (DU R -64;
Production of hyperstimulated manifestations in rats (Table I) Beckman Co., Tokyo, Japan) to evaluate the capillary permeability
At 48 h after the last injection, the ovarian weights in group in the peritoneal cavity and ovaries. • ϭ ovarian EB content (ng/mg tissue), # ϭ significantly lower expressed as the means Ϯ SEM. #: significantly lower than in rats than in rats receiving vehicle alone (P Ͻ 0.005), @ ϭ significantly receiving vehicle (RU486 0 mg/kg group) alone (P Ͻ 0.0001).*:
lower than in rats receiving vehicle alone (P Ͻ 0.05), significantly different (P Ͻ 0.0001). Numbers of animals are shown * ϭ significantly different (P Ͻ 0.03). Numbers of animals are in parentheses over each bar. P ϭ 6α-methyl-17α-hydroxyshown in parentheses over each bar. P ϭ 6α-methyl-17α-hydroxyprogesterone acetate.
progesterone acetate.
0.62, 0.47 Ϯ 0.08 µg; P Ͻ 0.05 and P Ͻ 0.0001, respectively). permeability in this model, depending on the dose administered. On the other hand, the peritoneal EB level in group II was
In the rats receiving 2.5 or 5 mg/kg, the ovarian weight was not significantly different from that of the control group, significantly lower than that in rats receiving the vehicle alone although the ovarian weights were significantly higher than in (198.21 Ϯ 14.69, 241 .64 Ϯ 14.83 versus 292.63 Ϯ 13.89 mg; the control group (P Ͻ 0.01). Similarly, the ovarian EB content P Ͻ 0.005, P Ͻ 0.05, respectively) ( Figure 2 ). The ovarian in group I (58.56 Ϯ 2.83 ng/mg) was significantly higher than EB content in the rats receiving 2.5, 5 or 10 mg/kg of RU486 in group II and the control group (27.96 Ϯ 5.93, 24.95 Ϯ 2.62 was significantly lower than that in the rats receiving the ng/mg; P Ͻ 0.0001, respectively), whereas no significant vehicle alone (47.95 Ϯ 2.42, 46.83 Ϯ 1.5 8 and 4 7.51 Ϯ 3.1 differences were observed between group II and the control. 5 versus 60.78 Ϯ 2.63 ng/mg wet weight tissue; P Ͻ 0.005) The serum concentration of oestradiol in group I (52.05 Ϯ (Figure 2 ). 9.38 pg/ml) was significantly higher than that in group II and The peritoneal irrigated fluid EB level in the rats receiving the control group (28.49 Ϯ 3.97, 19.36 Ϯ 4.12 pg/ml, P Ͻ progesterone concomitantly with RU486 was significantly 0.03 and P Ͻ 0.01, respectively). A similar result was obtained higher than in the rats receiving the same dose of RU486 for the serum concentration of progesterone (279.60 Ϯ 22.02 alone (6.97 Ϯ 0.54 versus 2.01 Ϯ 0.31 µg; P Ͻ 0.03) (Figure versus 52.42 Ϯ 11.18, 3 .70 Ϯ 0.72 ng/ml; P Ͻ 0.0001, 1). In addition, a similar result was obtained for the ovarian respectively). Furthermore, ascites formation and multiple EB content (57.82 Ϯ 5.07 versus 46.83 Ϯ 1.59 ng/mg; P Ͻ cystic ovaries with luteal or haemorrhagic cysts were found 0.03) (Figure 2 ). These results indicated that the decrease in in all rats of group I.
capillary permeability induced by RU486 injection was From these results, it was interpreted that there existed reversed by the concomitant administration of progesterone. manifestation of OHSS in group I. In the subsequent study, we utilized this stimulation protocol, i.e. 10 IU of eCG for 4
Analysis of peripheral oestradiol, progesterone and ACTH consecutive days followed by 30 IU HCG, as the treatment to concentrations produce the experimental model of OHSS.
There were no significant differences in the serum concentraEffect of RU486 and progesterone in the hyperstimulated rats tions of oestradiol and progesterone among any of the groups (Figure 3a and 3b, respectively). In the rats receiving 2.5, 5 or 10 mg/kg of RU486, the The plasma ACTH level in the rats receiving 20 mg/kg of peritoneal irrigated fluid EB content was significantly lower RU486 was significantly higher than that in the rats receiving than in the vehicle group (2.09 Ϯ 0.46, 2.01 Ϯ 0.31 and 2.70 0, 1, 5 or 10 mg/kg (2.88 Ϯ 0.78 versus 1.44 Ϯ 0.18, 1.25 Ϯ Ϯ 0.39 versus 8.75 Ϯ 0.62 µg; P Ͻ 0.0001, respectively). 0.06, 1.46 Ϯ 0.12 and 1.46 Ϯ 0.12 ng/ml; P Ͻ 0.01, However, the EB content in the rats receiving 20 mg/kg (10.76 respectively) (Figure 4 ). This augmentation of the plasma Ϯ 1.32 µg) was higher than that in the vehicle group, although ACTH level seemed to reflect the existence of an antinot significantly (P ϭ 0.06) (Figure 1 ). These results suggested that RU486 had two different effects on peritoneal capillary glucocorticoid effect of RU486 in this situation. RU486 is a synthetic steroid hormone that binds to the progesterone receptor and acts as a progesterone antagonist (Tanaka et al., 1993) . RU486 is reported to have a long halflife and a high affinity for progesterone and cortisol receptors, while it does not bind to the oestrogen receptor (Speroff et al., 1994) . The administration of the lower doses (2.5, 5 and 10 mg/kg) of RU486 decreased the capillary permeability in the present study. This may have resulted from progesterone receptor blockade by lower concentrations of RU486. In significantly. This was probably due to the anti-glucocorticoid No significant differences were obtained between any pairs of these effect of excess RU486 (Speroff et al., 1994) . In fact, an groups in the serum concentrations of oestradiol or progesterone. Numbers of animals are shown in parentheses over each bar. increase in the plasma ACTH level was observed by the P ϭ 6α-methyl-17α-hydroxy-progesterone acetate. administration of 20 mg/kg of RU486 in the present study, which might reflect the anti-glucocorticoid effect of this agent Discussion (Kettel et al., 1996) . Our finding that the ovarian weight decreased following the administration of RU486 is inconAn experimental model of OHSS was first documented by Polishuk and Shenker (1969) in adult rabbits, and was subsistent with the report on rats by Schoot et al. (1987) . This decrease in ovarian weight may have resulted from a decline sequently utilized by several investigators. Lindenbaum et al. (1980) failed to establish an experimental model of OHSS in of capillary permeability in the ovarian stroma. The maximal inhibitory effect of RU486 on the peritoneal irrigated fluid EB mature rats. However, in the present study, we used immature female rats, since immature animals are not influenced by the level was observed at 2.5-5 mg/kg. The administration of progesterone at the dosage of 10 mg/kg concomitantly with 5 corpus luteum from the previous cycles and since there is much information about the ovarian physiology in immature rats. mg/kg of RU486 reversed the decline in capillary permeability. This result suggests that progesterone may influence capillary The purpose of our first experiment was to produce hyperstimulated manifestations which might be utilized as an experipermeability in our OHSS experimental model. On the other hand, there were no significant changes of the serum concentramental model of OHSS in rats. Since the administration of eCG (10 IU daily) for 4 consecutive days followed by 30 IU tions of ovarian steroid hormones in the present study. An inhibitory effect of RU486 on progesterone synthesis has been HCG on the fifth day produced significant ovarian enlargement and increased capillary permeability in immature rats 48 h reported in the immature rat (Tanaka et al., 1993) , pregnant rats (Kawano et al., 1988) , and humans (Spitz et al., 1994) , after the HCG injection, we utilized this treatment protocol to produce an experimental model of OHSS in the subsequent while Telleria et al. (1994) reported that there was an increase in serum progesterone concentration after the administration study.
of RU486 in pro-oestrous rats. These discrepancies may be not shown). Therefore, it is conceivable that progesterone does due to the difference of the time of its administration.
not cause the increase in capillary permeability by itself but Bergqvist et al. (1993) demonstrated the existence of progesrather modulates the increased permeability caused by factor(s) terone receptors in the peripheral veins and suggested that this through the ovulatory process initiated by gonadotrophins. In implied hormonal control of vascular function. Moreover, fact, markedly elevated progesterone levels are often seen in Higuchi et al. (1995) detected the expression of progesterone clinical situations, whereas many of these individuals do not receptors in the human pelvic peritoneum by means of reverse develop into the clinical scenario of OHSS. Further studies transcription-polymerase chain reaction (RT-PCR). These are needed to clarify the interactions of several mediators in reports provide support for the possibility that progesterone the pathophysiology of clinical OHSS development. may have a modulatory role on peritoneal capillary perSeveral investigators reported that the ovarian-derived promeability.
renin to angiotensin cascade (ODPAC) may be related to the Yuen et al. (1979) reported elevated plasma concentrations pathogenesis of OHSS. Navot et al. (1987) demonstrated a of progesterone, in addition to oestradiol, during the clinical direct correlation between plasma renin activity and the severity phase of OHSS. Moreover, cultured human granulosa cells of OHSS. Morris et al. (1995b) found that angiotensin conobtained from women at risk of OHSS showed an increased verting enzyme inhibition caused a decrease in the incidence capacity for the synthesis of steroid hormones, including of OHSS in a rabbit model. On the other hand, Morris et al. progesterone (Leya et al., 1992) . The widely-known fact that (1995c) demonstrated that the administration of an angiotensin severe OHSS occurs frequently in association with pregnancy converting enzyme inhibitor appeared to lower the serum suggests an involvement of progesterone in the pathophysioprogesterone concentration in human stimulated cycles. These logy of this syndrome.
data are not inconsistent with the hypothesis that the ODPAC Lyons et al. (1994) and Morris et al. (1995a) reported that may stimulate the production of progesterone which then OHSS can be induced by endogenous or exogenous HCG.
induces OHSS. Indeed, the use of progesterone instead of HCG for luteal Vascular endothelial growth factor (VEGF) may contribute phase support is one practical method for attempting to reduce to the development of OHSS (McClure et al., 1994 ; Neulen the incidence of severe OHSS. However, HCG administration et al., 1995) . Charnock-Jones et al. (1993) observed that may induce a higher local progesterone concentration, especisteroids are probably involved in VEGF regulation in human ally in enlarged ovaries with multiple corpora lutea, rather endometrium. In addition, Torry et al. (1996) demonstrated than the administration of progesterone itself, and such a local temporal fluctuations of VEGF mRNA expression in the human increase of progesterone may play a role as the stimulatory endometrium and its increase in the secretory phase. These mediator for ovarian hyperstimulated manifestations. On the findings indicate the possibility that progesterone might partiother hand, the use of gonadotrophin-releasing hormone anacipate in the aetiology of OHSS through its modulatory action logues (GnRHa) to induce ovulation is reported to eliminate on VEGF in ovaries and peritoneum. Whether progesteroneeffectively the risk for developing OHSS, compared to the use dependent enhancement of VEGF activity may occur in our of HCG . This finding may provide support experimental model is now under investigation. for the hypothesis that the protracted luteinizing hormone Several inflammatory cytokines have been suggested to be (LH)-like activity rendered by HCG, which has a longer halfinvolved in the pathogenesis of OHSS. Orvieto et al. (1995) life than LH, with prolonged stimulation of the corpus luteum reported elevated intrafollicular interleukin (IL)-2 concentramay be involved in the pathophysiology of OHSS (Kol et al., tions in IVF cycle patients who developed OHSS, and high 1996). The sustained local level of progesterone derived from concentrations of IL-6 (Friedlander et al., 1993 ; Abramov these HCG-stimulated ovaries may conceivably contribute to et al., 1996) as well as IL-8 (Abramov et al., 1996) were the clinical features of this syndrome.
observed in the ascitic fluid of severe OHSS patients. On In clinical situations, RU486 is difficult to use as a therathe other hand, since the serum concentrations of IL-6 in peutic candidate for OHSS patients, because of its abortive gonadotrophin-stimulated cycles were significantly higher than effects (Thonneau et al., 1995) , except for the cases in which in the natural cycles, gonadotrophin may have a stimulatory elective cryopreservation of all embryos are performed in inrole on the IL-6 production (Loret de Mola et al., 1996) . An vitro fertilization (IVF) cycles. However, low-dose RU486 immunohistochemical study revealed that IL-6 was strongly administration was recently suggested to be effective in localized in human endometrial glandular and epithelial cells delaying the appearance of the endometrial implantation winduring the secretory phase compared to the proliferative phase dow which might have been advanced by the ovulation (Tabibzadeh et al., 1995) , supporting the contention that induction (Paulson et al., 1997) . Therefore, the administration progesterone may have an ability to stimulate IL-6 production of this agent set at a critical dose presents a possibility for its at least in endometrium. Based on these findings, the possibility use without its abortive side-effect in the luteal phase. To our exists that progesterone may stimulate the production of those knowledge, the therapeutic management using RU486 for cytokines which relate to the clinical phase of OHSS. Further OHSS patients has not been reported previously.
studies are needed to elucidate the exact mechanisms of the Polishuk and Schenker (1969) found no ovarian enlargement interactions between these cytokines and progesterone. or ascites formation when exogenous progesterone was given
In conclusion, the alterations in capillary permeability medito experimental animals. We also obtained similar results by administration of progesterone in immature female rats (data ated by gonadotrophins through luteal function may be influ-
